What You Should Know:
- New Day Diagnostics LLC announced it has entered into an agreement to acquire the assets of Epigenomics AG, a molecular diagnostics company focused on blood testing for the early detection of cancer.
- Under the terms of the agreement, New Day Diagnostics would acquire substantially all of Epigenomics AG’s assets and intellectual property.
- The acquisition would expand New Day Diagnostics’ portfolio in the cancer diagnostics space and include proprietary biomarker technology for the detection of methylated DNA in various cancer indications, including Epi proColon, a screening tool for the non-invasive detection of colorectal cancer.
